SOPHiA GENETICS (SOPH) investor relations material

Strategic vision and platform development

• Focused on capturing global healthcare data and applying AI to improve diagnosis and treatment since inception in 2011.

• Developed a cloud-based, technology-agnostic AI platform for precision medicine, compatible with all major sequencing technologies.

• Platform supports applications across oncology and rare disorders, analyzing over 2.5 million patients to date.

• Partnerships with leading sequencer companies and top global cancer centers drive data diversity and algorithm quality.

• Real-time data streaming from over 1,000 institutions in 75 countries enhances the platform's collective intelligence.

Business model, growth, and financial performance

• Straightforward revenue model: $100–$500 per patient, with 90%+ of revenue from genomic analysis.

• Achieved 400,000 analyses last year, with March volume surpassing 40,000 per month for the first time.

• Revenue guidance for 2026 is $92–$94 million, with targets to accelerate growth to 25–30% annually.

• Pharma business expected to shift from a drag in 2025 to a growth accelerator in 2026–2028, supported by major deals like AstraZeneca.

• Gross margin at 75%, with profitability targeted by end of 2027.

Market positioning and customer value

• Platform enables decentralized testing, reducing turnaround times from weeks to hours and lowering costs for institutions.

• Retains customer data control, supporting research and biopharma partnerships for new discoveries.

• Churn rate below 1%, with strong customer retention and expansion across applications.

• Land-and-expand strategy adds new clients and broadens use within institutions, with 124 new clients added recently.

• Seven of the top 10 global cancer institutes use the platform, validating its analytical performance.